Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
March 05, 2018 16:01 ET
|
Spring Bank Pharmaceuticals, Inc.
Spring Bank strengthens Board of Directors with the addition of aprominent biopharma R&D veteran HOPKINTON, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc....
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
February 20, 2018 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic...
Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21
February 12, 2018 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Conference Call to be Held at 8:30am Eastern Time HOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company...
Spring Bank Strengthens Management Team to Enhance Operations
January 09, 2018 08:30 ET
|
Spring Bank Pharmaceuticals, Inc.
Appoints Kevin Leach, Ph.D., as Vice President, Nonclinical & Translational Research Promotes Garrett Winslow to General Counsel HOPKINTON, Mass., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank...
Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
November 15, 2017 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
Low Dose of Inarigivir Soproxil (50mg) Monotherapy Demonstrates a Favorable Safety Profile and Significant Dose-Dependent Antiviral Activity, Meeting Both Primary Endpoints Conference Call Scheduled...
Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
November 07, 2017 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
October 31, 2017 06:45 ET
|
Spring Bank Pharmaceuticals, Inc.
Quarter highlighted by data presentations at two conferences and the initiation of research collaborations Confirms top-line results from the second inarigivir (formerly SB 9200) monotherapy dosing...
Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
October 20, 2017 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Inarigivir Phase 2 results confirm antiviral activity & novel mechanism of action Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the...
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
October 06, 2017 08:30 ET
|
Spring Bank Pharmaceuticals Inc.
HOPKINTON, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
October 02, 2017 08:30 ET
|
Spring Bank Pharmaceuticals Inc.
SB 11285 Shows Potent and Highly-Durable Anti-Tumor Activity in Several Tumor Models HOPKINTON, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a...